Zhongxin Finance, May 23. On the 23rd, Baike issued an announcement on abnormal fluctuations in stock trading, saying that the company's chickenpox vaccine cannot prevent monkeypox, and the company currently has no products related to monkeypox virus prevention.
The announcement stated that the company's stock trading within two consecutive trading days (May 23, 2022, May 20, 2022) The cumulative deviation of the closing price increase reached 30%. According to relevant regulations, it is an abnormal fluctuation of stock trading.
Baike Bio said that the company has noticed that some media have published reports on monkeypox virus infection cases in many countries and published reports on listed companies with monkeypox virus-related products or technical reserves, which involve the company.
On May 20, 2022, the company has responded to the relevant questions through the "SSE E Interactive" platform as follows: Monkeypox virus and smallpox virus belong to the genus Orthopoxvirus of the Poxviridae family, and are a viral zoonotic disease. It is transmitted from animals to people through direct and close contact, and can also be transmitted from person to person. The main routes of infection include blood and body fluids. The infectivity of monkeypox is far less than that of smallpox virus.
The varicella-zoster virus belongs to the Herpesviridae family and has no animal reservoirs. Humans are the only natural hosts and are transmitted through the respiratory tract.
The company's varicella vaccine cannot prevent monkeypox, and the company has no products related to the prevention of monkeypox virus.
In addition, the company has not found any media reports or market rumors that may have a greater impact on the company's stock trading price, nor has it found other major events that may have a greater impact on the company's stock price.
On the 23rd, Baike Biotech closed at 50.95 yuan per share, a single-day increase of 13.47%, and a turnover of 213 million yuan.